Net Health Benefit of Oral Targeted Cancer Drugs Varies
Oral targeted cancer drugs with a low net health benefit are less frequently prescribed than drugs with a medium or high net health benefit.
Oral targeted cancer drugs with a low net health benefit are less frequently prescribed than drugs with a medium or high net health benefit.
This Viewpoint discusses the importance of concentrating research efforts and clinical training on sexual and gender minority individuals who survive cancer, particularly on sexual rehabilitation.
KIM-1 levels were evaluated using a high-sensitivity electrochemiluminescence assay.
TTFields therapy plus best supportive care increased time to first intracranial progression by 10.6 months in patients with NSCLC brain metastases.
New or worsening anemia may not reduce the clinical benefit derived from ruxolitinib treatment in patients with myelofibrosis.
It could be skin cancer. The Movember movement encourages men to raise awareness of health issues that can affect them
Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
In an interview with Targeted Oncology, Sarah Sammons, MD, discussed an analysis of the DESTINY-Breast03 trial, highlighting the need for further research on trastuzumab deruxtecan…
Sema7A controls neutrophil chemotaxis in vitro and the formation of platelet-neutrophil complexes in vivo.Sema7A influences the early phase of inflammation
After donating his liver to his father, son changes career path